Search Results

Medica EasyQC Hematocrit Control assayed controls are intended to be used to monitor and evaluate the analytical performance of the Medica EasyStat for the measurement of hematocrit by conductivity. For In Vitro Diagnostic Use

Medica EasyQC Hematocrit Control is a specially formulated, two-level, aqueous liquid material intended to monitor hematocrit measurement by the Medica EasyStat analyzer. Medica EasyQC Hematocrit Control provides a convenient method of performing periodic QC checks for laboratories selecting to measure liquid QC material as a part of their quality assurance program. Medica EasyQC Hematocrit Control is an electrolyte solution with conductivity at two levels appropriate to simulate clinically relevant hematocrit concentrations useful to evaluate the measurement of the Medica EasyStat Analyzer. Medica EasyQC Hematocrit Control is a non-hazardous aqueous solution containing no biological materials.

The provided document for the Medica EasyQC Hematocrit Control is a 510(k) summary, which focuses on establishing substantial equivalence to a predicate device rather than detailing specific acceptance criteria and a comprehensive study proving performance against those criteria. As such, much of the requested information (like specific acceptance criteria, sample sizes, ground truth methodologies derived from expert consensus or pathology, MRMC studies, or detailed standalone performance) is not present in the provided text.

The document states that "Tests were conducted to verify specific performance requirements: a) Real-time evaluation of products with the same formulation and failure mode to support stability. b) Test precision", but it does not elaborate on the specific acceptance criteria for these tests nor the results in a quantitative manner.

Based on the provided information, here's what can be extracted and what is missing:

Acceptance Criteria and Reported Device Performance

Note: The document does not explicitly state quantitative acceptance criteria or detailed-performance results for the Medica EasyQC Hematocrit Control itself beyond its characteristics. The comparison table below highlights characteristics used to establish substantial equivalence, not performance against specific criteria.

Detailed Study Information (Based on availability in the document)

1. Sample size used for the test set and the data provenance:

   • Test Set Sample Size: Not specified. The document mentions "Tests were conducted" for stability and precision but does not provide details on the number of samples or measurements in these tests.
   • Data Provenance: Not specified (e.g., country of origin, retrospective/prospective).

2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

   • This information is not provided. The device is a quality control material, not a diagnostic device that requires ground truth established by medical experts in the same way an AI diagnostic algorithm would.

3. Adjudication method (e.g., 2+1, 3+1, none) for the test set:

   • This information is not applicable/provided. As a quality control material and not a diagnostic tool requiring interpretation, this type of adjudication would not be relevant.

4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

   • No. This device is a hematocrit control material, not an AI-assisted diagnostic tool. Therefore, an MRMC study and analysis of human reader improvement with AI assistance are not relevant and were not performed.

5. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

   • This concept is not applicable to a hematocrit control solution.

6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

   • For a control material, the "ground truth" would typically refer to the known, assigned value of the control material (e.g., its target hematocrit concentration). The document does not specify how these target values were established or verified, beyond stating it's an "electrolyte solution with conductivity at two levels appropriate to simulate clinically relevant hematocrit concentrations."

7. The sample size for the training set:

   • This information is not applicable/provided. This device is a manufactured chemical control solution, not a machine learning algorithm that requires a training set.

8. How the ground truth for the training set was established:

   • This information is not applicable/provided for the reasons mentioned above.

Summary of the Study:

The provided document describes a 510(k) premarket notification for the "Medica EasyQC Hematocrit Control." The "study" presented is primarily a comparison of the new device's technological characteristics, formulation, and intended use against legally marketed predicate devices (specifically, RNA QC900 Hematocrit Control, K955630) to establish substantial equivalence.

The document states that "Tests were conducted to verify specific performance requirements: a) Real-time evaluation of products with the same formulation and failure mode to support stability. b) Test precision." However, no quantitative data, methods, or results of these tests are provided in this summary. The conclusion drawn is that the "Comparison of technological characteristics, formulation and intended use to predicate devices listed in this summary support the claim of substantial equivalence."

This 510(k) summary focuses on demonstrating that the new control device is as safe and effective as existing legally marketed devices, rather than establishing its performance against a detailed set of quantitative acceptance criteria through extensive clinical trials or complex AI model validation studies.

Ask a specific question about this device